| Browse All

Phio Pharmaceuticals Corp. (PHIO)

Healthcare | Biotechnology | King Of Prussia, United States | NasdaqCM
1.29 USD +0.02 (1.575%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 1.30 +0.01 (0.767%) ⇧ (April 17, 2026, 7:17 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 1:09 p.m. EDT

PHIO appears to be a highly volatile and speculative stock, with a current price of $1.21 near its 52-week low of $0.813. The stock has shown mixed price movements in the recent 14-day period, with some upward trends but also dips. The forward PE and trailing EPS are negative, indicating potential financial distress. The stock's low market cap and high short ratio suggest it may be heavily shorted, which could lead to a short squeeze. However, the recent news headlines show positive developments, such as positive trial results and new equity programs, which may indicate potential for future growth. Despite this, the lack of a dividend history and the negative fundamentals make it a risky investment for both short-term and long-term investors. The forecasting model's low p-values suggest that the model may not be reliable for short-term price prediction. Overall, PHIO is a speculative play with potential upside but significant downside risk.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.111829
AutoETS0.115147
AutoTheta0.187509
AutoARIMA0.423941

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 76%
H-stat 1.10
Ljung-Box p 0.000
Jarque-Bera p 0.449
Excess Kurtosis -0.42
Attribute Value
Sector Healthcare
Market Cap 14,986,253
Forward P/E -2.08
Beta 0.81
Website https://phiopharma.com

Info Dump

Attribute Value
52 Week Change -0.55123675
Address1 411 Swedeland Road
Address2 Suite 23-1080
All Time High 6,379,560.0
All Time Low 0.813
Ask 1.33
Ask Size 2
Average Daily Volume10 Day 142,400
Average Daily Volume3 Month 3,802,521
Average Volume 3,802,521
Average Volume10Days 142,400
Beta 0.808
Bid 1.28
Bid Size 2
Book Value 1.734
City King Of Prussia
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 1.29
Current Ratio 16.027
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 1.31
Day Low 1.275
Display Name Phio Pharmaceuticals
Dividend Date 1,579,046,400
Earnings Timestamp End 1,755,518,400
Earnings Timestamp Start 1,754,996,340
Ebitda -9,217,000
Ebitda Margins 0.0
Enterprise To Ebitda 0.656
Enterprise Value -6,044,747
Eps Current Year -0.95
Eps Forward -0.62
Eps Trailing Twelve Months -1.45
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 1.18864
Fifty Day Average Change 0.10135996
Fifty Day Average Change Percent 0.0852739
Fifty Two Week Change Percent -55.123676
Fifty Two Week High 4.19
Fifty Two Week High Change -2.9
Fifty Two Week High Change Percent -0.6921241
Fifty Two Week Low 0.813
Fifty Two Week Low Change 0.47699994
Fifty Two Week Low Change Percent 0.58671576
Fifty Two Week Range 0.813 - 4.19
Financial Currency USD
First Trade Date Milliseconds 1,336,656,600,000
Float Shares 11,548,127
Forward Eps -0.62
Forward P E -2.080645
Free Cashflow -5,056,500
Full Exchange Name NasdaqCM
Full Time Employees 6
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -4,618,000
Has Pre Post Market Data 1
Held Percent Insiders 0.06
Held Percent Institutions 0.082100004
Implied Shares Outstanding 11,617,251
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,720,137,600
Last Split Factor 1:9
Long Business Summary Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Long Name Phio Pharmaceuticals Corp.
Market us_market
Market Cap 14,986,253
Market State POSTPOST
Max Age 86,400
Message Board Id finmb_140969529
Most Recent Quarter 1,767,139,200
Net Income To Common -8,698,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 14,986,252
Number Of Analyst Opinions 1
Open 1.29
Operating Cashflow -7,979,000
Operating Margins 0.0
Payout Ratio 0.0
Phone 610 947 0251
Post Market Change 0.009900093
Post Market Change Percent 0.7674491
Post Market Price 1.2999
Post Market Time 1,776,467,853
Previous Close 1.27
Price Eps Current Year -1.3578947
Price Hint 4
Price To Book 0.74394464
Profit Margins 0.0
Quick Ratio 15.695
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.02
Regular Market Change Percent 1.5748
Regular Market Day High 1.31
Regular Market Day Low 1.275
Regular Market Day Range 1.275 - 1.31
Regular Market Open 1.29
Regular Market Previous Close 1.27
Regular Market Price 1.29
Regular Market Time 1,776,456,000
Regular Market Volume 102,853
Return On Assets -0.42332
Return On Equity -0.69948
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 11,617,250
Shares Percent Shares Out 0.049200002
Shares Short 571,887
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 528,245
Short Name Phio Pharmaceuticals Corp.
Short Percent Of Float 0.0495
Short Ratio 1.44
Source Interval 15
State PA
Symbol PHIO
Target High Price 14.0
Target Low Price 14.0
Target Mean Price 14.0
Target Median Price 14.0
Total Cash 21,031,000
Total Cash Per Share 1.81
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.45
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.65806
Two Hundred Day Average Change -0.36806
Two Hundred Day Average Change Percent -0.22198232
Type Disp Equity
Volume 102,853
Website https://phiopharma.com
Zip 19,406